We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here


Mantle Cell Lymphoma Treatment Challenges

Monday, February 9, 2015

Associate professor Jia Ruan, M.D., Ph.D., talks to OncLive about initial treatment methods for mantle cell lymphoma (MCL).  Because MCL is not common, it is often difficult to determine the best initial treatment, says Ruan. The majority of previous studies have focused on combination chemotherapy treatments, which do not always cure MCL and can often be too toxic for the many MCL patients who are elderly.  A recent phase II study explored the combination of rituximab and lenalidomide to determine if the regimen was both non-toxic and effective for the treatment of MCL. 

Read more reports about her research on the New Developments in Lympoma blog.